AIRLINK 66.25 Decreased By ▼ -0.55 (-0.82%)
BOP 5.68 Increased By ▲ 0.01 (0.18%)
CNERGY 4.64 Increased By ▲ 0.01 (0.22%)
DFML 22.80 Increased By ▲ 0.48 (2.15%)
DGKC 70.30 Increased By ▲ 0.54 (0.77%)
FCCL 20.34 Increased By ▲ 0.72 (3.67%)
FFBL 29.49 Decreased By ▼ -0.71 (-2.35%)
FFL 9.95 Increased By ▲ 0.05 (0.51%)
GGL 10.09 Increased By ▲ 0.04 (0.4%)
HBL 115.26 Decreased By ▼ -0.44 (-0.38%)
HUBC 129.44 Decreased By ▼ -1.07 (-0.82%)
HUMNL 6.70 Decreased By ▼ -0.04 (-0.59%)
KEL 4.36 Increased By ▲ 0.01 (0.23%)
KOSM 4.91 Increased By ▲ 0.11 (2.29%)
MLCF 37.10 Decreased By ▼ -0.09 (-0.24%)
OGDC 131.41 Decreased By ▼ -2.14 (-1.6%)
PAEL 22.50 Decreased By ▼ -0.10 (-0.44%)
PIAA 26.55 Decreased By ▼ -0.15 (-0.56%)
PIBTL 6.54 Increased By ▲ 0.29 (4.64%)
PPL 112.81 Decreased By ▼ -1.14 (-1%)
PRL 28.43 Increased By ▲ 1.28 (4.71%)
PTC 16.15 Increased By ▲ 0.02 (0.12%)
SEARL 58.58 Decreased By ▼ -1.12 (-1.88%)
SNGP 65.75 Decreased By ▼ -0.75 (-1.13%)
SSGC 11.07 Decreased By ▼ -0.14 (-1.25%)
TELE 8.94 No Change ▼ 0.00 (0%)
TPLP 11.56 Increased By ▲ 0.22 (1.94%)
TRG 69.25 Decreased By ▼ -0.11 (-0.16%)
UNITY 23.90 Increased By ▲ 0.45 (1.92%)
WTL 1.35 Decreased By ▼ -0.01 (-0.74%)
BR100 7,307 Decreased By -10.1 (-0.14%)
BR30 23,976 Decreased By -129.9 (-0.54%)
KSE100 70,370 Decreased By -113.7 (-0.16%)
KSE30 23,134 Decreased By -68.3 (-0.29%)

British drugmaker GSK said on Tuesday its antibody-based COVID-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.

The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.

Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.

UK approves GSK Covid drug, appears effective against Omicron

"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK Chief Scientific Officer Hal Barron said.

GSK and Vir have been engineering so-called pseudoviruses that feature major coronavirus mutations across all suspicious variants that have emerged so far, and have run lab tests on their vulnerability to sotrovimab treatment.

Comments

Comments are closed.